EpimAb Biotherapeutics
PrivateLast Round
IPO Announced
Dec 18, 2025
Total Funding Raised
$249M
Company Overview
EpimAb Biotherapeutics is a biopharmaceutical company specializing in the research and development of innovative bispecific antibody therapeutics using its proprietary FIT-lg technology.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
EpimAb Biotherapeutics Comps
Public and private peers based on sector, stage, and business model.
EpimAb Biotherapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| IPO Announced | Dec 18, 2025 | ||||
| Series C | Mar 22, 2021 | ||||
| Series B Extension | Mar 11, 2020 | ||||
| Series B | Jun 5, 2019 | ||||
| Series A | Apr 25, 2017 |
Key People
Founding team and executive leadership
EpimAb Biotherapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| SCVC | Series B |
| Yanchuang Capital | Series C |
| 招银国际金融有限公司 | IPO, Series C |
| CITIC Securities | IPO |
| SDIC Innovation Investment Management | Series C, Series B |
| Hony Capital | Series C |
| Decheng Capital | Series C, Series A, Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 17, 2026
Presenting novel prodrug T-cell engager platform at AACR Annual Meeting.
- Feb 10, 2026
Partner Almirall filed CTA for bispecific antibody technology.
EpimAb Biotherapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about EpimAb Biotherapeutics's valuation, stock price, and market status.
